INTRODUCTION
Once it has reached the lamina propria, the gliadin would react with the tissue transglutaminase (tTG) -i.e. the enzyme catalyzing glutamine's deamidation-thus creating a transglutaminasegliadin deamidated complex [5] . The deamidated peptide would be picked up by HLA DQ2 or DQ8 molecules on the surface of antigen-presenting cells (APC), and would be "presented" to the CD4 + T helper 1 (Th1). These Th1-cells would produce high levels of pro-inflammatory Despite this pathogenesis, it seems that both Th1/Th17-and Th2-mediated diseases may co-exist in cases of CD [10] . It is well known that CD patients show a particular tendency for multiple autoimmune and/or allergic and/or immuno-mediated disorders (IMD) over their lifetime [11] [12] , which supports this possibility.
To date, only hypotheses exist to explain the observed split in the association between the type of T lymphocyte-mediated reaction and CD. CD is frequently associated to other Th1/Th17-IMD M a n u s c r i p t To date, a gluten free diet (GFD) is considered the only treatment for CD. Numerous papers have investigated the effects of CD therapy on the incidence and prognosis of coexisting or subsequent IMD but thus far they have reported contradictory results [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] . The aims of our study were: 1) to establish the prevalence of IMD at the time and after CD diagnosis in a large sample of adult individuals; 2) to identify any possible changes in immune response after commencement of GFD, in particular with regard to shifts from Th1/Th17-to Th2-immune response or vice versa; and 3) to investigate the potential role of GFD in reducing and/or preventing IMD in adult CD patients. M a n u s c r i p t
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METHODS
Between September 2011 and February 2015 we carried out a prospective study including all consecutive adult CD patients (age > 18 years) followed up at our Gastrointestinal Unit (Tertiary Centre for Food Intolerance and CD, "Federico II" University, Naples, Italy). In accordance with current guidelines, CD diagnosis was made in the presence of Marsh ≥ 2 histology associated with both anti-tissue Transglutaminase (a-tTG) IgA > 7 U/ml and positive anti-endomysial Information on the presence/absence of any allergic, atopic, or autoimmune disease preceding CD diagnosis was gathered at the time of the first consultation and during the study period each study participant underwent clinical examination and laboratory tests at least once a year.
In particular, we assessed the clinical and biochemical presence of: vitiligo, allergic rhinitis, ankylosing spondylitis, Sjogren syndrome, multiple sclerosis, scleroderma, nephrotic syndrome, ulcerative colitis, psoriasis, polymyalgia rheumatica, urticaria, IgA nephropathy, lichen planus, systemic lupus erythematosus, type 1 diabetes mellitus (or latent autoimmune diabetes in adults), Hashimoto's thyroiditis, eczema, atopic dermatitis, primary sclerosing cholangitis, Crohn's disease, allergic conjunctivitis, primary biliary cirrhosis, Grave's disease, asthma, alopecia, rheumatoid arthritis and other allergies. Analysis of variance (ANOVA) was performed with and without adjustment for covariates. The odd ratio (OR) for quantifying the statistical difference between the dichotomous variables was also calculated. All results were considered statistically significant when p value < 0.05.
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RESULTS
During the study period, 1255 CD patients referred to our Centre were enrolled (males/females 258/997). At the time of CD diagnosis, mean age + SD was 28,1 + 15,7; mean a-tTG serum level was 98,7 + 108,2 U/mL; all patients were positive for EMA. Histological exam showed a Marsh 1 grade in 64 patients (5%), Marsh 2 grade in 50 (4%), Marsh 3A in 171 (13.7%), Marsh 3B in 311 (24.8%), and Marsh 3C in 659 (52.5%). Main patient characteristics and diagnostic results are reported in Table 2 .
Data collected through medical history showed that 257 patients out of 1255 (20.5%) suffered from at least one immunological/allergic IMD before the diagnosis of CD. Of these, 150 (58.4%)
suffered from Th1/Th17-mediated and 107 (41.6%) from Th2-mediated diseases (p=0.7). Table   3 reports the prevalence of all IMD found in our population.
In the 5-years study period following CD diagnosis, 682 patients out of 1255 (54.3%) developed other immuno-mediated diseases regardless of whether they were following a strict GFD (mean a-tTG levels were 1,2 + 0,8 U/mL; negative EMA). Of these 682 patients, 391 (57.3%) developed a Th1/Th17-related disease, and 291 (42.7%) a Th2-mediated condition (p=0.8). Also in this case, Table 3 summarizes all results relating to the type of IMD present and their prevalence at the time of diagnosis and after GFD.
We compared the prevalence of immuno-mediated diseases pre-and post-CD diagnosis and found that there was no significant 'switch' from Th1/Th17-mediated to Th2-mediated response or vice versa (58.4% and 41.6%, respectively, pre-CD diagnosis; 57.3% and 42.7% post-CD diagnosis; p=0.9). The number of patients with either a Th1-or a Th2-mediated disease increased over time in the period following CD diagnosis (20.5% vs 54.3%; p<0.01; OR 1.9;95% C.I. 1.5-2.1). Of the 1255 participants in the study, 150 (12%) were affected by Th1/Th17-IMD at the time of CD diagnosis and 391 (31%) following CD diagnosis (p<0.01; OR 2.6); 107
A c c e p t e d M a n u s c r i p t Table 3) .
No correlation was found between the occurrence of autoimmune/allergic diseases and any of the following variables: age at the time of CD diagnosis, a-tTG serum levels at the time of diagnosis and at follow-up, Marsh grade and clinical symptoms (P = NS). Table 4 better clarifies these results.
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DISCUSSION
At present, the only treatment for CD is represented by gluten free diet (GFD).
Numerous papers have explored the effects of GFD on the incidence and course of CDassociated IMD, often reporting contradictory results. Most of these studies, however, supported the hypothesis of a protective effect of GFD with regard to the occurrence of CD-associated IMD
[12].
Our study investigated the relationship between GFD and CD-associated IMD with a specific focus on the relative prevalence of Th1/Th17-and Th2-mediated diseases before and after the start of GFD. Our results suggest that we should re-examine the widely shared view that GFD is a magic bullet for the treatment of all pathological conditions associated with CD. Our study included a large population of patients suffering from CD (1255 in total), which strengthens our results and suggestions for practice. The present study confirms the outcomes firstly reported by reported a prevalence of autoimmune disease in CD patients of about 30%. In our study, we did not find any correlation between the development of IMD and the age at the time of diagnosis. It seems to us that, once started, the "autoimmune waterfall", cannot be stopped by GFD, thus leading to an increased risk of developing IMD. About this issue, a different conclusion was reached by Elli et al
[30] reporting a quite protective effect of longstanding gluten exposure on the occurrence of IMD.
In effect, the Authors found that the increment of 1 year in CD diagnosis corresponded to a lower risk of developing IMD (HR 0.30).
With regard to the CD-related IMD found in our study population, the most frequent were:
Hashimoto's thyroiditis (8.2% before vs 24% after CD diagnosis; p<0.01; OR 1.6 (IC:1.5-1.7)); psoriasis (0.7% before vs 2.7% after CD diagnosis; p<0.01; OR 1.5 (IC 1.3-1.8)); type 1 diabetes mellitus (1.8% before vs 0.2% after CD diagnosis; p<0.01; OR 0.08 (IC 0.01-0.4)).
The association between CD and thyroid disorders is well known. In a study conducted by Hadithi et al.
[38], 4.8% of Dutch patients with Hashimoto's thyroiditis had CD, and 12% of patients with CD had Hashimoto's thyroiditis. In a prospective study of 27 adult coeliac patients, Metso et al.
[32] found that CD subjects had an elevated anti-TPO levels, which continued to increase despite GFD. Thyroid atrophy also progressed while on a GFD. The Authors suggested that GFD seemed The association between CD and type 1 diabetes mellitus is well established. In the majority of cases (more than 90%), the diagnosis of diabetes precedes that of CD, as confirmed by Greco et al.
[45]. However, some studies have reported that diabetes onset can frequently occur in patients already diagnosed with CD. Valerio et al.
[46], for example, demonstrated that diagnosis of CD prior to onset of diabetes denotes a subgroup of patients with a more severe clinical presentation of diabetes and higher prevalence of multiple autoimmune diseases, suggesting that GFD does not help to prevent other autoimmune disorders which have already been triggered. In our study population diabetes was present in 1.8% of patients before CD diagnosis, but after starting GFD only 0.2% presented diabetes (p<0.01; OR 0.08). This result could be explained by the fact that ours is an adult population. In effect, type 1 diabetes mellitus usually presents in adolescent and young adults, except for latent autoimmune diabetes of the adults (LADA) which affected 2 patients in the study.
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In our paper we consider also the Th2-mediated diseases, such as allergic diseases. No statistically significant differences were found between the percentage of Th2-predominant disorders before and after CD diagnosis (41.6% and 42.7%, respectively, P = NS), although the absolute number of patients affected by a Th2 disease increased during GFD (107 vs 291, p < 0.01). Therefore, it seems that the coeliac population is also particularly susceptible to allergic diseases, even after starting GFD.
However, there were some limitations to our study. In this paper, we used a-tTg as a surrogate M a n u s c r i p t 21 
